Filing Details

Accession Number:
0000939767-24-000132
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-09-25 19:32:57
Reporting Period:
2024-09-23
Accepted Time:
2024-09-25 19:32:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
939767 Exelixis Inc. EXEL Biological Products, (No Disgnostic Substances) (2836) 043257395
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1599803 Jeffrey Hessekiel C/O Exelixis, Inc.
1851 Harbor Bay Parkway
Alameda CA 94502
Evp & General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-09-23 25,000 $26.38 605,325 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 999 Indirect By 401(k)
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 29, 2024.
  2. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.18 to $26.58. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
  3. Includes 236,022 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock.
  4. Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of September 22, 2024.